

Jenprad (LEVOSULPIRIDE)

25mg, 50mg
Tablets

۲۵ ملی گرام
۵۰ ملی گرام گولیاں
جینپریڈ
(لیوسل پیرائیڈ)

Composition:

Jenprad 25mg:

Each tablet contains:

Levosulpiride.....25mg

Jenprad 50mg:

Each tablet contains:

Levosulpiride.....50mg

(Innovator's Specifications)

CHEMICAL CLASSIFICATION:

Levosulpiride is substituted benzamide; chemically it is S-(-)N-(1-ethylpyrrolidine-2-yl-methyl-5-) Sulfamoyl-benzamide.

THERAPEUTIC CLASSIFICATION:

Atypical neuroleptic with stereoselective antidopaminergic action.

PROPERTIES:

The biochemical, pharmacological and clinical data obtained from the two sulphiride isomers indicate that the antidopaminergic action, both on a central and peripheral level, is due to the levogyre enantiomer (levosulpiride). **Jenprad** exhibits a clear antidepressive, Anti cenesthopathic, uninhibiting and resocializing action. Due to this hallucinolytic and deliriolytic action, it is effective against acute and chronic schizophrenia.

For depression, **Jenprad** is administered at lower dosage than those used on patients with schizophrenia. It is suggested that those low dosages involve a preferential action on the presynaptic DA receptors, thus producing a functional increase of dopaminic transmission and stimulating monotolic and psychic action. The antipsychotic effects of Levosulpiride generated at high dosage may be due to a blocking of the post synaptic DA-receptors, although these effects are not as characteristic as those produced by classic neuroleptic agents.

Jenprad exerts its actions at dosage which is 2-3 times lower than those of the racemic molecules, which entails a better tolerability and reduced occurrence of collateral effects

Sedation, antimuscarinic effects, hypotension and extrapyramidal disorders are less of a problem than with most other neuroleptics.

PHARMACOKINETICS:

After oral administration, the bioavailability of Levosulpiride is about 30% Peak plasma concentrations occur after about 3 hours and it has plasma half life of about 9.7 hours. It is mostly eliminated by the kidneys in the urine.

INDICATIONS:

Jenprad is indicated in the treatment of following disorders.

- ★ Dyspepsia.
- ★ Endogenous and reactive depressive states.
- ★ Somatic disturbances.
- ★ Acute and chronic schizophrenia, especially recommended for negative symptoms (after disorders).

DOSAGE:

Endogenous and reactive, depressive states/somatic disturbances:

- ★ For Adults: 2-3 tablets of 50mg daily.

Acute and chronic schizophrenia:

- ★ For Adults: 4-6 tablets of 50mg daily.

Dyspepsia:

- ★ For Adults: 2-3 tablets of 25mg daily.

Maintenance Therapy: The dosage may be progressively lowered. When treating aged patients the dosage must be carefully established by the physician who must consider a possible reduction in the dosage mentioned above

CONTRAINDICATIONS:

As with other neuroleptics, Levosulpiride is also contraindicated in patients with hyperprolactinemic tendency, mammary dysplasias and malignant mastopathies.

PRECAUTIONS:

Jenprad is to be given with caution in epilepsies, manic states, manic stages of manic-

depressive psychosis, cases of hypertension in patients suspected to be carriers of pheochromocytoma and in patients showing signs of cardiac insufficiency.

WARNINGS:

As with other neuroleptics, the association of Levosulpiride with typical neuroleptics demand particular medical care and attention. In case of potentially fatal complex symptoms, known as malignant Neuroleptic Syndrome (hyperpyrexia, muscular rigidity, akinesia, vegetative disturbances, irregularities of pulse and arterial pressure, perspiration, arrhythmias, alteration of the conscious conditions, or numbness and coma), under such circumstances, the treatment may be suspended, or should be continued, if considered essential and patients must be carefully monitored.

USE DURING PREGNANCY AND LACTATION:

Not to be used during presumed or confirmed pregnancy and during the lactation period.

DRUG INTERACTION:

As with other neuroleptics or substituted benzamide, the concomitant use of Levosulpiride with therapeutic doses of Sucralfate, or an antacid containing aluminum and magnesium hydroxide may reduce mean oral bioavailability of Levosulpiride.

SIDE EFFECTS:

Numbness, a sense of vertigo and asynchronisms may occur. Patients under treatment must be made aware of these risks in order to avoid driving vehicles and attending to operations demanding total attention, due to their potential dangers. In very rare cases, psychomotor excitement, neurovegetative disturbances and allergic phenomena have been observed. Isolated cases of an increase in body weight have been reported following prolonged treatment. All these effects are of a modest and reversible nature. Galactorrhea and alterations of the libido, observed on particular occasions, are conducive to a reversible effect of Levosupiride on the functionality of the hypothalamus-pituitary-gonadic axis. which is similar to that known in many neuroleptics.

STORAGE:

Store in a dry place below 30° C and protect from sunlight.

Keep all medicines out of reach of children.

To be sold on prescription of a registered medical practitioner only.

PRESENTATION:

Jenprad 25mg:

Alu-Alu blister of 2x10's.

Jenprad 50mg:

Alu-Alu blister of 2x10's.

خوراک:

ڈاکٹر کی ہدایت کے مطابق استعمال کریں

ہدایات:

دوا کو ۳ ڈگری سینٹی گریڈ سے کم درجہ حرارت پر رکھیں۔

دھوپ اور نمی سے بچائیں۔

بچوں کی پہنچ سے دُور رکھیں۔

صرف رجسٹرڈ ڈاکٹر کے نسخے پر فروخت کریں۔



JENNER

Manufactured by:

JENNER PHARMACEUTICALS (Pvt) Ltd.

Plot # 3, M-2, Pharma zone, 26th Km Lahore
Sharikpur Road, Sheikhpura-Pakistan.